cancer patients miss out on innovative new treatments
Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes.
February 7, 2022
by pharmatimes
Four-drug combo therapy shows benefit for newly-diagnosed myeloma patients
A four-drug combination therapy has shown significant benefit for patients with newly diagnosed myeloma, according to a new analysis led by researchers from The Institute of Cancer Research, London (ICR).
July 27, 2021
by pharmatimes
NICE’s decision not to approve Zytiga ‘frustrating’, says ICR
The National Institute of Health and Care Excellence (NICE) has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the drug in 2020.
July 16, 2021
by pharmatimes
Scientists identify link between genetic changes and rare childhood cancer rhabdomyosarcoma
Genetic changes may help to improve decision making for the treatment of the rare and aggressive form of childhood cancer rhabdomyosarcoma, according to a new international study led by researchers at the Institute of Cancer Research, London (ICR).
June 28, 2021
by pharmatimes
Researchers find CD38-targeting drugs may show promise against prostate cancer
A new study suggests that drugs which target the CD38 protein molecule may show promise against prostate cancer by ‘reawakening’ the body’s immune response against this tumour type.
May 11, 2021
by pharmatimes
PARP inhibitors could exploit weaknesses in a range of cancers
PARP inhibitors – a type of drug most commonly used to treat ovarian and breast cancers – could offer a new way of targeting a range of cancers with a particular gene defect in the PBRM1 gene, according to researchers.
April 26, 2021
by pharmatimes
Experts call for advanced radiotherapy funding to address COVID-19 cancer care backlog
The Institute for Cancer Research, London (ICR) is urging the government to invest in advanced radiotherapy in a bid to address the backlog in NHS cancer care that has accumulated during the COVID-19 pandemic.
April 13, 2021
by pharmatimes
Cancer research in the UK faces ‘perfect storm’ of funding cuts
The Institute of Cancer Research, London (ICR) has made an appeal to Prime Minister Boris Johnson after identifying a ‘perfect storm’ of funding cuts that could impact cancer research in the UK.
April 1, 2021
by pharmatimes
ICR’s ‘resistance-busting’ drug advances into Phase I trial
The Institute of Cancer Research, London (ICR) has announced that its ‘resistance-busting’ drug EP0042 has entered a Phase I clinical trial in patients with cancers including acute myeloid leukaemia (AML).
March 19, 2021
by pharmatimes
Researchers identify existing drug’s potential for triple negative breast cancer
Researchers at The Institute of Cancer Research, London (ICR) have identified an already approved breast cancer drug which could have promise in the treatment of triple negative breast cancer (TNBC).
January 29, 2021
by pharmatimes
ICR researchers identify potential new treatment for drug-resistant prostate cancer
Researchers from The Institute of Cancer Research, London (ICR) and the Royal Marsden NHS Foundation Trust have revealed the mechanism of action for a ‘promising’ new prostate cancer treatment.
January 13, 2021
by pharmatimes
ICR scientists create 3D protein structure for new therapy development
The UK Institute of Cancer Research, London (ICR) researchers have created a three-dimensional (3D) structure of a complex of molecules for new therapies.
December 21, 2020
by pharmaceutical-technology